Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics
Show others and affiliations
Number of Authors: 492019 (English)In: mAbs, ISSN 1942-0862, E-ISSN 1942-0870, Vol. 11, no 1, p. 94-105Article in journal (Refereed) Published
Abstract [en]

The increased interest in using monoclonal antibodies (mAbs) as a platform for biopharmaceuticals has led to the need for new analytical techniques that can precisely assess physicochemical properties of these large and very complex drugs for the purpose of correctly identifying quality attributes (QA). One QA, higher order structure (HOS), is unique to biopharmaceuticals and essential for establishing consistency in biopharmaceutical manufacturing, detecting process-related variations from manufacturing changes and establishing comparability between biologic products. To address this measurement challenge, two-dimensional nuclear magnetic resonance spectroscopy (2D-NMR) methods were introduced that allow for the precise atomic-level comparison of the HOS between two proteins, including mAbs. Here, an inter-laboratory comparison involving 26 industrial, government and academic laboratories worldwide was performed as a benchmark using the NISTmAb, from the National Institute of Standards and Technology (NIST), to facilitate the translation of the 2D-NMR method into routine use for biopharmaceutical product development. Two-dimensional H-1,N-15 and H-1,C-13 NMR spectra were acquired with harmonized experimental protocols on the unlabeled Fab domain and a uniformly enriched-N-15, 20%-C-13-enriched system suitability sample derived from the NISTmAb. Chemometric analyses from over 400 spectral maps acquired on 39 different NMR spectrometers ranging from 500 MHz to 900 MHz demonstrate spectral fingerprints that are fit-for-purpose for the assessment of HOS. The 2D-NMR method is shown to provide the measurement reliability needed to move the technique from an emerging technology to a harmonized, routine measurement that can be generally applied with great confidence to high precision assessments of the HOS of mAb-based biotherapeutics.

Place, publisher, year, edition, pages
2019. Vol. 11, no 1, p. 94-105
Keywords [en]
monoclonal antibody (mAb) therapeutics, NISTmAb, higher order structure, nuclear magnetic resonance spectroscopy (NMR), comparability, chemometrics
National Category
Biological Sciences Other Medical Sciences not elsewhere specified
Identifiers
URN: urn:nbn:se:su:diva-166601DOI: 10.1080/19420862.2018.1544454ISI: 000456959200006PubMedID: 30570405OAI: oai:DiVA.org:su-166601DiVA, id: diva2:1300696
Available from: 2019-03-29 Created: 2019-03-29 Last updated: 2019-03-29Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Aubin, YvesKeizer, David W.Widmalm, GöranReardon, Patrick N.Yanaka, SaekoKeire, David
By organisation
Department of Organic Chemistry
In the same journal
mAbs
Biological SciencesOther Medical Sciences not elsewhere specified

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 21 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf